Abstract
KIR4.1 Antibodies as Biomarkers in Multiple Sclerosis.
Highlights
An enzyme-linked immunosorbent assay (ELISA) large-scale screening with 397 Multiple sclerosis (MS) patients, 329 persons with other neurological diseases, and 59 healthy donors was performed
Antibodies against KIR4.1 were observed in 46.9% of patients with MS, but were essentially absent in people with other neurological diseases and healthy donors
We would like to carefully raise the possibility that the serum IgG reactivity against KIR4.1 might present an epiphenomenon and there could be an additional target for autoreactive B cells beyond the central nervous system (CNS)
Summary
In a clinical study published in 2012 in the New England Journal of Medicine, Srivastava and colleagues screened serum samples aiming to identify CNS-specific antibodies in MS [7]. The authors identified the glial potassium channel KIR4.1 as one of the serum antibody targets in MS patients. Srivastava et al concluded that KIR4.1 is a CNS-specific target of the autoantibody response in a subgroup of patients with MS.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
